Golden
Bain Capital Life Sciences

Bain Capital Life Sciences

Bain Capital Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally.

Founded in 1984, Bain Capital is an alternative investment firm. They manage $105 billion in assets across their eighteen global locations. Their Bain Capital Life Sciences is a venture capital fund which specializes in buyouts, inflection capital, growth capital, turnaround and private equity investments in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and life science technology sectors.



Bain Capital Life Science was initially raised in May 2017 at $720 million.

Investment

Bain Capital Life Sciences has invested in Annexon Biosciences, Aptinyx, Arcutis Biotherapeutics, Cerevel Therapeuticvs, Constellation Pharmaceuticals, Dicerna Pharmaceuticals Inc., Gynesonics, Hugel, InlfaRx, Kestra Medical Technologies, Marinus Pharmaceuticals, Rapid Micro Biosystems, Replimune, SpringWorks Therapeutics, Solid Biosciences and ViaCyte.



Bain Capital Life Sciences has exited their investments in SpringWorks Therapeutics, Dicerna Pharmaceuticals, Solid Biosciences, Aptinyx, Replimune Group, and InflaRx.

Timeline

Funded Companies

5 Results
Company
Company
Description
Description
Website
Website
Industry
Industry
Location
Location

Solid Biosciences is a Cambridge, Massachusetts-based biotechnology company.

Gynesonics is a Redwood City, California-based healthcare company.

InflaRx is a Germany-based company.

People

Name
Role
LinkedIn







Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References